COGNITION THERAPEUTICS INC
CGTX$95M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaPURCHASE25 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Jun 30, 2026
15wMarket Overview
Stock performance and key metrics
CGTX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
CT1812
Early Alzheimer's Disease
C105
Cognition Disorders
golexanolone
Primary Biliary Cholangitis (PBC)
Active Treatment- CT1812 100 mg
Alzheimer Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CT1812 | Phase 2 | Early Alzheimer's Disease | - | - |
C105 | Phase 2 | Cognition Disorders | - | - |
golexanolone | Phase 2 | Primary Biliary Cholangitis (PBC) | - | - |
Active Treatment- CT1812 100 mg | Phase 2 | Alzheimer Disease | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply